PAHC
NEUTRAL
$53.88
Live
Phibro Animal Health Corporation · NASDAQ
Target $51.2
(-5.0%)
$16.16
52W Range
$60.08
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 17, 2026
Market cap
$2.18B
P/E
23.84
ROE
31.8%
Profit margin
6.3%
Debt/Equity
2.33
Dividend yield
0.89%
AI Analysis
AI-powered fundamental assessment
Confidence
85%
PAHC exhibits strong fundamental health with a Piotroski F-Score of 7/9 and an impressive ROE of 31.80%, indicating efficient operational management. While the stock trades at a significant premium to its Graham Number ($20.42), it remains below its growth-based intrinsic value of $66.67. However, the bullish fundamental outlook is heavily countered by aggressive insider selling from the CEO and a very bearish technical trend (10/100). The company is in a high-growth phase with strong EPS beats, but the divergence between financial health and insider sentiment warrants a neutral stance.
Key Strengths
Strong Piotroski F-Score (7/9) indicating robust financial health
Exceptional Return on Equity (ROE) of 31.80%
Strong revenue growth (20.90% YoY) and consistent earnings beats
Excellent short-term liquidity with a Current Ratio of 3.05
Positive forward P/E compression (from 23.84 to 15.90)
Key Risks
Aggressive insider selling, specifically concentrated in the CEO
High Debt/Equity ratio of 2.33
Severe bearish technical trend (10/100)
Significant premium over defensive fair value (Graham Number)
Low dividend yield (0.89%) providing little downside protection
AI Fair Value Estimate
Based on comprehensive analysis
$56.2
+4.3% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
70
Strong
55
88
92
75
40
AI Verdict
Fundamental Strength vs. Sentiment Weakness
Key drivers: Piotroski F-Score, Insider Selling, Revenue Growth, Technical Trend
Confidence
90%
Value
55/100
P/E 23.84, PEG 1.68, Graham $20.42
Positives
- Trades below growth-based intrinsic value
- Reasonable Forward P/E
Watchpoints
- High Price/Book (6.57)
- Far above Graham Number
Future
88/100
Ref Growth rates and EPS track record
Positives
- 20.9% Revenue Growth
- Consistent quarterly EPS surprises
- Strong earnings trajectory
Watchpoints
- Sustainability of 752% YoY earnings growth is unlikely
Past
92/100
Ref Historical price performance and earnings beats
Positives
- 1Y Return of +224.4%
- Consistent beat on estimates (3/4 last quarters)
Watchpoints
No urgent risks highlighted.
Health
75/100
Ref Piotroski F-Score and Liquidity ratios
Positives
- Piotroski F-Score 7/9
- Current Ratio 3.05
Watchpoints
- Debt/Equity 2.33
Dividend
40/100
Ref Yield and Payout
Positives
- Low payout ratio (21.24%) suggests room for growth
Watchpoints
- Very low yield (0.89%)
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$53.88
Analyst Target
$51.2
Upside/Downside
-5.0%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for PAHC and closest competitors.
Updated 2026-04-16
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
PAHC
Phibro Animal Health Corporation
Primary
|
+144.3% | +265.7% | +224.4% | +40.4% | +2.6% | -8.8% |
|
BHC
Bausch Health Companies Inc.
Peer
|
-78.1% | -29.4% | -24.3% | -12.7% | -17.7% | -15.3% |
|
ACHC
Acadia Healthcare Company, Inc.
Peer
|
-61.4% | -66.0% | -16.5% | +8.2% | +51.5% | -8.2% |
|
DAWN
Day One Biopharmaceuticals, Inc.
Peer
|
-8.7% | +69.0% | +205.7% | +189.6% | +0.6% | +0.1% |
|
AHG
Akso Health Group
Peer
|
+24.4% | +547.7% | +88.2% | +30.8% | +77.3% | +85.2% |
PAH
Phibro Animal Health Corporation
Primary
5Y
+144.3%
3Y
+265.7%
1Y
+224.4%
6M
+40.4%
1M
+2.6%
1W
-8.8%
BHC
Bausch Health Companies Inc.
Peer
5Y
-78.1%
3Y
-29.4%
1Y
-24.3%
6M
-12.7%
1M
-17.7%
1W
-15.3%
ACH
Acadia Healthcare Company, Inc.
Peer
5Y
-61.4%
3Y
-66.0%
1Y
-16.5%
6M
+8.2%
1M
+51.5%
1W
-8.2%
DAW
Day One Biopharmaceuticals, Inc.
Peer
5Y
-8.7%
3Y
+69.0%
1Y
+205.7%
6M
+189.6%
1M
+0.6%
1W
+0.1%
AHG
Akso Health Group
Peer
5Y
+24.4%
3Y
+547.7%
1Y
+88.2%
6M
+30.8%
1M
+77.3%
1W
+85.2%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
23.84
Forward P/E
15.9
PEG Ratio
1.68
P/B Ratio
6.57
P/S Ratio
1.49
EV/Revenue
1.97
EV/EBITDA
12.6
Market Cap
$2.18B
Profitability
Profit margins and return metrics
Profit Margin
6.29%
Operating Margin
14.71%
Gross Margin
32.3%
ROE
31.8%
ROA
8.34%
Growth
Revenue and earnings growth rates
Revenue Growth
+20.9%
Earnings Growth
+752.0%
Q/Q Revenue Growth
+20.9%
Q/Q Earnings Growth
+762.1%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
2.33
High debt
Current Ratio
3.05
Strong
Quick Ratio
1.03
Good
Cash/Share
$1.85
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.4B
Gross Margin
35.5%
Op. Margin
13.5%
Net Margin
7.3%
Total Assets
$1.4B
Liabilities
$1.1B
Equity
$0.3B
Debt/Equity
3.23x
Operating CF
$0.0B
CapEx
$-0.0B
Free Cash Flow
$0.0B
FCF Yield
43%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-06
$N/A
2026-02-04
$0.87
+29.9% surprise
2025-11-05
$0.73
+21.1% surprise
2025-08-27
$0.57
+9.3% surprise
Healthcare Sector Comparison
Comparing PAHC against 393 companies in the Healthcare sector
(24 bullish, 129 neutral, 240 bearish)
P/E Ratio
23.84
This Stock
vs
90.61
Sector Avg
-73.7%
(Discount)
Return on Equity (ROE)
31.8%
This Stock
vs
-101.52%
Sector Avg
-131.3%
(Below Avg)
Profit Margin
6.29%
This Stock
vs
-12.47%
Sector Avg
-150.4%
(Weaker)
Debt to Equity
2.33
This Stock
vs
3.4
Sector Avg
-31.5%
(Less Debt)
Revenue Growth
20.9%
This Stock
vs
124.21%
Sector Avg
-83.2%
(Slower)
Current Ratio
3.05
This Stock
vs
4.56
Sector Avg
-33.0%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
PAHC
Phibro Animal Health Corporation
|
NEUTRAL | $2.18B | 23.84 | 31.8% | 6.3% | $53.88 | |
|
BHC
Bausch Health Companies Inc.
|
BEARISH | $2.19B | 6.79 | 563.2% | 3.6% | $5.91 | Compare |
|
ACHC
Acadia Healthcare Company, Inc.
|
BEARISH | $2.17B | - | -41.0% | -33.3% | $23.52 | Compare |
|
DAWN
Day One Biopharmaceuticals, Inc.
|
NEUTRAL | $2.22B | - | -22.7% | -67.8% | $21.46 | Compare |
|
AHG
Akso Health Group
|
BEARISH | $2.14B | - | -68.3% | -% | $2.5 | Compare |
PAHC
Phibro Animal...
NEUTRAL
Mkt Cap
$2.2B
P/E
23.8
ROE
31.8%
Price
$53.88
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-31 | BENDHEIM JACK CLIFFORD | Chief Executive Officer | Sale | 14,080 | $756,834 |
| 2026-03-26 | BENDHEIM JACK C | Chief Executive Officer | Sale | 21,120 | $1,166,105 |
| 2026-03-19 | BENDHEIM JACK C | Chief Executive Officer | Sale | 22,880 | $1,198,818 |
| 2026-03-13 | BENDHEIM JACK CLIFFORD | Chief Executive Officer | Sale | 5,280 | $258,245 |
| 2026-03-12 | BENDHEIM JACK CLIFFORD | Chief Executive Officer | Stock Award | 100,000 | - |
| 2026-02-26 | BENDHEIM JACK C | Chief Executive Officer | Sale | 21,120 | $1,103,938 |
| 2026-02-20 | BENDHEIM JACK C | Chief Executive Officer | Sale | 14,080 | $715,775 |
| 2026-02-18 | BENDHEIM JACK C | Chief Executive Officer | Sale | 14,080 | $727,646 |
| 2026-02-11 | BENDHEIM JACK C | Chief Executive Officer | Sale | 72,198 | $3,737,711 |
| 2026-02-09 | DAVID GLENN C | Chief Financial Officer | Stock Award | 30,000 | - |
| 2026-02-05 | BENDHEIM JACK C | Chief Executive Officer | Sale | 110,842 | $5,362,103 |
| 2026-02-05 | BENDHEIM JACK C | Chief Executive Officer | Stock Award | 185,000 | - |
| 2026-02-04 | BENDHEIM JACK C | Chief Executive Officer | Sale | 13,180 | $545,473 |
| 2026-02-04 | BENDHEIM JACK C | Chief Executive Officer | Stock Award | 30,000 | - |
| 2026-01-30 | BENDHEIM JACK C | Chief Executive Officer | Sale | 13,465 | $540,037 |
BENDHEIM JACK CLIFFORD
Chief Executive Officer
2026-03-31
14,080 shares
·
$756,834
BENDHEIM JACK C
Chief Executive Officer
2026-03-26
21,120 shares
·
$1,166,105
BENDHEIM JACK C
Chief Executive Officer
2026-03-19
22,880 shares
·
$1,198,818
BENDHEIM JACK CLIFFORD
Chief Executive Officer
2026-03-13
5,280 shares
·
$258,245
BENDHEIM JACK CLIFFORD
Chief Executive Officer
2026-03-12
100,000 shares
BENDHEIM JACK C
Chief Executive Officer
2026-02-26
21,120 shares
·
$1,103,938
BENDHEIM JACK C
Chief Executive Officer
2026-02-20
14,080 shares
·
$715,775
BENDHEIM JACK C
Chief Executive Officer
2026-02-18
14,080 shares
·
$727,646
BENDHEIM JACK C
Chief Executive Officer
2026-02-11
72,198 shares
·
$3,737,711
DAVID GLENN C
Chief Financial Officer
2026-02-09
30,000 shares
BENDHEIM JACK C
Chief Executive Officer
2026-02-05
110,842 shares
·
$5,362,103
BENDHEIM JACK C
Chief Executive Officer
2026-02-05
185,000 shares
BENDHEIM JACK C
Chief Executive Officer
2026-02-04
13,180 shares
·
$545,473
BENDHEIM JACK C
Chief Executive Officer
2026-02-04
30,000 shares
BENDHEIM JACK C
Chief Executive Officer
2026-01-30
13,465 shares
·
$540,037
Insider transactions can signal confidence or concerns about company prospects
SEC Filings
Recent regulatory filings from the SEC EDGAR database
8-K
8-K
10-Q
8-K
8-K
10-Q
8-K
DEF 14A
10-K
PAHC filed its annual 10-K report on August 27, 2025, which includes comprehensive disclosures on its business operations, risk factors, and financial condition. While specific financial metrics were not provided in the excerpts, the filing contains detailed management analysis and a dedicated section outlining the company's primary risk factors.
Data sourced from SEC EDGAR. AI summaries generated automatically.
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
HOLD
5 analysts
Citigroup
2026-04-15
Neutral
JP Morgan
2025-11-07
Overweight
Overweight
Past News Coverage
Recent headlines mentioning PAHC from our newsroom.
Newest → oldest
No matching news yet.